Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

17.60 -0.17 (-0.96%)
Streaming Delayed Price Updated: 11:50 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
London Cancel
Brazilian Cosan is up 0.43% despite desperate Covid-19 outbreaks along the Amazon. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Earth Day
Once again the exchanges are unsure if they want to go up or down. 
Via Talk Markets
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member. 
Via Investor's Business Daily
Is Novocure a Buy?
Once a stock goes up 50% in a single day, it can be hard to keep the momentum going. 
Via The Motley Fool
Why Investors Are So Excited About Novocure
The company's Tumor Treating Fields therapy looks very promising in treating lung cancer. 
Via The Motley Fool
Currency Manipulation
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53. 
Via Talk Markets
Stock Market Rally Keeps Rising As Treasury Yields Fall Despite Strong Earnings, Economic Data; Goldman, Nvidia, Coinbase In Focus
Tumbling yields and strong economic data fueled stocks. Goldman earnings, Nvidia news and the Coinbase IPO were in focus. 
Via Investor's Business Daily
Topics Initial Public Offering Stocks
Exposures Securities Market US Equities
This Stock Just Popped 40%. Here's Why It Can Continue to Crush the Market
Novocure has provided stellar returns over the last five years, now up 17 times. Recent positive news may keep its stock going up. 
Via The Motley Fool
Happy News Day
The stock markets are in clover because March retail sales hit 9.8% according to the Department of Commerce. 
Via Talk Markets
Stunning Market Debut
Wednesday brought a zip into the accounts of many financial stocks thanks to a boom result from Goldman Sachs GS, which boosted its competitors' prices. 
Via Talk Markets
Cancer Therapy Novocure Stock Flashes Renewed Technical Strength
Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
JP Morgan raised Southwest Airlines Co. (NYSE: LUV) price target from $44 to $66. Southwest Airlines shares rose 1% to $63.79 in pre-market trading. Keybanc boosted Public... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021
Upgrades For Cardlytics Inc (NASDAQ:CDLX), Craig-Hallum upgraded the previous rating of Hold to Buy. For the fourth quarter, Cardlytics had an EPS of $0.05, compared to... 
Via Benzinga
Electric Cancer Cure
Most US stocks were down on fear of inflation and financial risks but then rose after lunch. 
Via Talk Markets
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
Exposures Product Safety
Why Novocure Stock Skyrocketed Today
The oncology specialist's investigational cancer treatment could be a game-changer. 
Via The Motley Fool
50 Biggest Movers From Yesterday
Gainers Mackinac Financial Corporation (NASDAQ: MFNC) shares surged 60.7% to close at $21.16 on Tuesday after the company, and Nicolet Bankshares, jointly announced the execution... 
Via Benzinga
Mid-Afternoon Market Update: Dow Falls 75 Points; vTv Therapeutics Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.22% to 33,669.76 while the NASDAQ rose 0.80% to 13,960.92. The S&P also rose, gaining 0.28% to 4,139.55. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With NVCR Stock And VTV Stock Today?
Novocure Ltd (NASDAQ: NVCR) shares are trading higher after a data monitoring committee said the interim analysis of the company's Phase 3 LUNAR trial would be accelerated.... 
Via Benzinga
Stocks Mixed Following JNJ Vaccine Update, Inflation Data
The Dow is off more than 100 points. The S&P 500 notched a new intraday high. 
Via Talk Markets
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers NovoCure (NASDAQ:NVCR) shares rose 42.08% to $187.38 during Tuesday's regular session. Trading volume for NovoCure's stock is 11.4 million as of 12:32 EST... 
Via Benzinga
Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer Treatment
A trial examining the use of Novocure's tumor-treating field technology in non-small cell lung cancer patients could enroll fewer patients over a shorter period, based on recommendations by an... 
Via The Motley Fool
Mid-Day Market Update: Nasdaq Jumps 100 Points; Avenue Therapeutics Shares Slide
Midway through trading Tuesday, the Dow traded down 0.34% to 33,630.52 while the NASDAQ rose 0.75% to 13,953.54. The S&P also rose, gaining 0.12% to 4,133.03. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Mackinac Financial Corporation (NASDAQ: MFNC) jumped 57.6% to $20.75 after the company, and Nicolet Bankshares, jointly announced the execution of a definitive merger... 
Via Benzinga
NVCR Stock: The Cancer Therapy News That Has Novocure Shares Skyrocketing Today
NVCR stock is skyrocketing on Tuesday after cancer treatment firm Novocure received great news regarding its phase 3 tumor treatment trial. 
Via InvestorPlace
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.